HEMOSTATIC SYSTEM ACTIVATION STUDY

止血系统激活研究

• 批准号: 6188216
• 负责人: J P KISTLER
• 金额: $ 8.89万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-09-05 至 2002-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6188216
• 关键词: antithrombins; aspirin; cardiovascular disorder chemotherapy; cardiovascular disorder epidemiology; cerebral ischemia /hypoxia; clinical research; disease /disorder proneness /risk; drug resistance; hemostatics; human subject; human therapy evaluation; longitudinal human study; peptide analog; platelet aggregation inhibitors; prothrombin; radioimmunoassay; relapse /recurrence; stroke; thrombin; warfarin

The specific aim of the Hemostatic System Activation Study (HAS) is to investigate the level of activity of the hemostatic system in patients in the Warfarin Aspirin Recurrent Stroke Study (WARSS). The radioimmunoassay measurement of the peptide fragment F1+2, a by-product of the conversion of prothrombin to thrombin, will be the indicator of the level of activity of the hemostatic system. Whether or not antithrombotic therapy is more beneficial than antiplatelet therapy in preventing recurrent stroke, HAS will provide an analysis of the actual level of in vivo thrombin generation associated with the INR achieved in the WARSS population. A higher mean F1+2 is expected in the aspirin treated cryptogenic stroke patients as compared to the aspirin treated non-cryptogenic stroke patients. A lower mean F 1+2 in the warfarin treated patients as compared to those on aspirin is expected. Some patients, however, may be resistant to the antithrombotic effect of warfarin as measured by a high F 1+2 value when their INR is in the WARSS therapeutic range of 1.4 to 2.8. The INR should correlate inversely with the F 1+2 and HAS will assess whether that relationship is constant over time. The association between F 1+2 and vascular risk factors (age, sex, hypercholesterolemia, hypertension, diabetes, smoking) and primary and secondary stroke subtypes will be studied. Other aims are to correlate F 1+2 level with data obtained in the APASS, PICSS and GENESIS substudies of WARSS, thereby enhancing the information obtained from them.

止血系统激活研究 (HAS) 的具体目的是 调查患者止血系统的活动水平 华法林阿司匹林复发性中风研究（WARSS）。 这 副产物肽片段 F1+2 的放射免疫测定 凝血酶原向凝血酶的转化率，将作为以下指标： 止血系统的活性水平。 无论是否 抗血栓治疗比抗血小板治疗更有益 预防复发性中风，HAS 将提供实际情况的分析 体内凝血酶生成水平与达到的 INR 相关 在 WARSS 人群中。 阿司匹林的平均 F1+2 预计较高 与阿司匹林治疗的隐源性中风患者相比 非隐源性中风患者。 华法林的平均 F 1+2 较低 预计接受治疗的患者与服用阿司匹林的患者相比。 一些 然而，患者可能对其抗血栓作用产生抵抗。 当 INR 处于正常值时，华法林的 F 1+2 值较高 WARSS治疗范围为1.4至2.8。 INR 应该相关 与 F 1+2 成反比，HAS 将评估这种关系是否成立 随着时间的推移是恒定的。 F 1+2 与血管风险之间的关联 因素（年龄、性别、高胆固醇血症、高血压、糖尿病、 将研究吸烟）以及原发性和继发性中风亚型。 其他目标是将 F 1+2 水平与 APASS 中获得的数据相关联， WARSS 的 PICSS 和 GENESIS 子研究，从而增强了信息 从他们那里获得的。